This is a routine execution of a previously announced restructuring plan. No immediate trading signal. Monitor the next 10-Q for updates on the restructuring's financial impact and any further headcount reductions.
TBPH drugs
TBPH drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 24 $17.27entry
- T+1 · 5mo ago +0.69%α +0.55% · $17.39
- T+5 · 5mo ago −1.68%α −3.39% · $16.98
- T+20 · 4mo ago −2.66%α −4.60% · $16.81
- T+60 · 2mo ago −1.33%α −4.17% · $17.04
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Theravance Biopharma disclosed the planned departure of SVP Development and Head of Ireland Office, Dr. ine Miller, effective November 15, 2026, under a compromise agreement tied to the restructuring announced in March 2026. The filing includes a grant of 18,750 RSUs and a $250,000 pension contribution. This is a routine, previously anticipated executive exit with no unexpected C-suite changes.
Key Facts
- Dr. ine Miller, SVP Development and Head of Ireland Office, will terminate employment on November 15, 2026.
- Departure is part of the restructuring announced by the company in March 2026.
- Dr. Miller received a grant of 18,750 restricted share units on June 19, 2026.
- The company will make a special pension contribution of $250,000 within 30 days of the termination date.
- CEO Rick E. Winningham remains in place; no other executive changes disclosed.
Financial Impact
Total disclosed cash cost of $250,000 pension contribution plus 18,750 RSUs; immaterial relative to $854M market cap.
Risk Factors
- Restructuring may signal ongoing operational challenges or cost pressures.
- Further executive departures could indicate deeper organizational issues.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-076857 |
| Document: 0001104659-26-076857-index-headers.html | 0001104659-26-076857 |
| Document: 0001104659-26-076857-index.html | 0001104659-26-076857 |
| Document: 0001104659-26-076857.txt | 0001104659-26-076857 |
Track record
12 reports on TBPH
3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +2.11% at T+1 after the Mar 3, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 4/10 Entry price pending
- Oct 5, 20266w ago 15-12G Bearish 7/10 No price data
- Sep 25, 20267w ago SC 13D/A Neutral 4/10 Entry $17.04 No price data
- Sep 23, 20267w ago 25-NSE Bearish 7/10 Entry $17.05 No price data
- Aug 25, 202611w ago DEFA14A Neutral 4/10 Entry $17.03 to $17.03 · 0.00% −0.23% vs SPY
- Aug 21, 202612w ago DEFM14A Bullish 7/10 Entry $17.01 to $17.05 ▲ +0.24% +0.76% vs SPY
- Aug 11, 202613w ago PREM14A Bullish 7/10 Entry $16.91 to $17.06 ▲ +0.89% +1.95% vs SPY
- Aug 10, 202614w ago 8-K Bullish 7/10 Entry $16.91 to $17.06 ▲ +0.89% +1.80% vs SPY
- Jun 29, 202620w ago 8-K Bullish 7/10 Entry $17.06 to $16.86 ▼ −1.17% −0.89% vs SPY
- Jun 23, 202620w ago 8-K Neutral 2/10 Viewing Entry $17.27 to $16.81 ▼ −2.66% −4.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers